多西他赛单药每周方案与GP方案治疗老年晚期非小细胞肺癌的疗效比较

【目的】对比分析以铂类为基础的GP（吉西他滨＋顺铂）联合化疗和多西他赛单药每周方案一线治疗老年Ⅲb～Ⅳ期非小细胞肺癌的近期疗效和毒副作用。【方法】58例Ⅲb～Ⅳ期从未接受过化疗的老年非小细胞肺癌患者,多西他赛组（n=31）给予多西他赛35mg／m^2,d1、d8、d15,28d为一疗程,GP组（n=27）给予吉西他滨1g／m^2,d1、d8,顺铂25mg／m^2,d1～3,21d为1疗程,两疗程后评价客观疗效及不良反应。【结果】两纽有效率：多西他赛纽25．8％,GP组25．9％（P〉0．05）;多西他赛组粒细胞减少、肝毒性及胃肠道反应显著低于GP组（P〈0．05）。【结论】多西他赛单药每周方案治疗非小细胞肺癌,疗效与GP方案相似,但毒副反应较GP方案显著减少,可作为拒绝接受标准化疗的老年晚期非小细胞肺癌患者的一线治疗。

Comparison of GP Regimen and Docetaxel in First Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

[Objective] To compare the clinical efficacy and toxicity between weekly docetaxel mofiotherapy and GP （gemcitabine ＋ cisplatin） regimen in first line treatment of Ill b~ IV stage non-small cell lung cancer （NSCLC） in elderly patients. [Methods] Fifty eight cases with stage Ⅲ b- Ⅳ NSCLC proved pathologically were enrolled in this study and were randomized into docetaxel group （ n =31, 35 mg/m^2 on d1 , d8 , d15 Ⅳ, 28 days as a cycle） and GP group （ n =27, gemcitabine 1 g/m^2 on d1 ,d8, and cisplatin 25 mg/m^2 on d1-3, 21 days as a cycle）. The efficacy and adverse effects were evaluated after two cycles of treatment. [Results] The response rate of docetaxel group was 25.8%, and that of GP group was 25.9% （ P 〉0.05）. The incidence of neutropenia, liver damage and alimentary tract reaction in docetaxel group were lower than those in GP group （ P 〈0.05）. [Conclusion] Compared with GP regimen, weekly docetaxel monotherapy for advanced NSCLC has similar response rate, but has lower toxicity and better tolerance. It can be accepted as a first line treat ment for elderly patients with advanced NSCLC.